Inovio Pharmaceuticals, Inc. (Nasdaq: INO) announced plans to sell shares of its common stock and accompanying warrants in an underwritten public offering, according to a press release dated July 29, 2026.

The biotechnology company said it intends to grant the underwriter a 30-day option to purchase additional shares and/or warrants equal to up to 15% of the securities offered, under the same terms and conditions. All securities in the proposed offering will be sold by Inovio.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement related to the offering was filed with the Securities and Exchange Commission on July 2, 2026, and declared effective by the SEC on July 10, 2026.

The company noted the offering is subject to market conditions, and there is no assurance as to whether, when, or on what terms the offering may be completed.